Department of Radiation Oncology, Klinikum Offenbach, Starkenburgring 66, 63069 Offenbach, Germany.
Radiat Oncol. 2013 May 8;8:115. doi: 10.1186/1748-717X-8-115.
To report the clinical outcome of high dose rate brachytherapy as sole treatment for clinically localised prostate cancer.
Between March 2004 and January 2008, a total of 351 consecutive patients with clinically localised prostate cancer were treated with transrectal ultrasound guided high dose rate brachytherapy. The prescribed dose was 38.0 Gy in four fractions (two implants of two fractions each of 9.5 Gy with an interval of 14 days between the implants) delivered to an intraoperative transrectal ultrasound real-time defined planning treatment volume. Biochemical failure was defined according to the Phoenix Consensus and toxicity evaluated using the Common Toxicity Criteria for Adverse Events version 3.
The median follow-up time was 59.3 months. The 36 and 60 month biochemical control and metastasis-free survival rates were respectively 98%, 94% and 99%, 98%. Toxicity was scored per event with 4.8% acute Grade 3 genitourinary and no acute Grade 3 gastrointestinal toxicity. Late Grade 3 genitourinary and gastrointestinal toxicity were respectively 3.4% and 1.4%. No instances of Grade 4 or greater acute or late adverse events were reported.
Our results confirm high dose rate brachytherapy as safe and effective monotherapy for clinically organ-confined prostate cancer.
报告高剂量率近距离放射治疗作为单一治疗局限性前列腺癌的临床结果。
2004 年 3 月至 2008 年 1 月，共对 351 例临床局限性前列腺癌患者进行了经直肠超声引导的高剂量率近距离放射治疗。规定的剂量为 38.0Gy，分为 4 个剂量（两个植入物，每个植入物为 9.5Gy，两个植入物之间间隔 14 天），植入物在术中经直肠超声实时定义的计划治疗体积内进行。生化失败根据凤凰共识定义，毒性使用不良事件通用毒性标准 3.0 版进行评估。
中位随访时间为 59.3 个月。36 个月和 60 个月的生化控制和无转移生存率分别为 98%、94%和 99%、98%。毒性按事件评分，急性 3 级泌尿生殖系统毒性为 4.8%，无急性 3 级胃肠道毒性。晚期 3 级泌尿生殖系统和胃肠道毒性分别为 3.4%和 1.4%。未报告任何 4 级或更高级别的急性或晚期不良事件。
我们的结果证实，高剂量率近距离放射治疗是一种安全有效的局限性前列腺癌单一治疗方法。
